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Novel classes of broad-spectrum antibiotics are
needed to treat multidrug-resistant pathogens. The
arylomycin class of natural products inhibits a prom-
ising antimicrobial target, type I signal peptidase
(SPase), but upon initial characterization appeared
to lack whole-cell activity against most pathogens.
Here, we show that Staphylococcus epidermidis,
which is sensitive to the arylomycins, evolves resis-
tance via mutations in SPase and that analogous
mutations are responsible for the natural resistance
of Staphylococcus aureus, Escherichia coli, and
Pseudomonas aeruginosa. We identify diverse
bacteria lacking these mutations and demonstrate
that most are sensitive to the arylomycins. The
results illustrate that the arylomycins have a broad-
spectrum of activity and are viable candidates for
development into therapeutics. The results also raise
the possibility that naturally occurring resistance
may have masked other natural product scaffolds
that might be developed into therapeutics.
INTRODUCTION
The clinical and agricultural use of antibiotics impose a relentless
selection pressure on bacteria that has driven the evolution of
multidrug resistance in many pathogens and novel classes of
antibiotics are needed (Fischbach and Walsh, 2009; Hancock,
2007). While the potency and spectrum of known antibiotics
have been improved through derivatization, modern efforts to
discover novel classes of broad-spectrum antibiotics have
largely failed, highlighting the unique challenges associated
with antibiotic development (Payne et al., 2007). First, bacterial
pathogens are extremely diverse, and only a handful of proteins
and biochemical processes are sufficiently conserved across all
bacteria to warrant consideration as antibiotic targets (Bumann,
2008; Silver, 2007). Second, all bacteria possess at least one
lipid bilayer, a peptidoglycan-based cell wall, and efflux systems
that reduce the accessibility of many targets (Poole, 2005). Given
these challenges, it is perhaps not surprising that most antibi-
otics that have reached the clinic belong to one of a small
number of natural product classes, whose activities have likelyChemistry & Biology 17, 1223–123been optimized over eons of evolution (Newman and Cragg,
2007; von Nussbaum et al., 2006). Unfortunately, it is believed
that most, if not all, of the broad-spectrum scaffolds produced
by the known culturable strains of bacteria have already been
identified (Baltz, 2006).
The arylomycins and related lipoglycopeptides (Figure 1)
constitute a recently discovered class of natural product antibi-
otics that inhibit the type I signal peptidases (SPases) of both
Gram-positive and Gram-negative bacteria in vitro (Kulanthaivel
et al., 2004; Paetzel et al., 2004; Schimana et al., 2002). However,
the initially reported spectrum of the arylomycins appeared
prohibitively narrow for drug development, with no activity
against most bacteria tested, including the important human
pathogens Staphylococcus aureus, Escherichia coli, and Pseu-
domonas aeruginosa (Kulanthaivel et al., 2004; Roberts et al.,
2007; Schimana et al., 2002). Indeed, antibiotic activity of the ar-
ylomycins was originally only demonstrated against Strepto-
coccus pneumoniae (Kulanthaivel et al., 2004) and the soil
bacteria Rhodococcus opacus and Brevibacillus brevis (Schi-
mana et al., 2002). However, we recently demonstrated that
the potencies of a natural arylomycin, arylomycin A2, and of
a synthetic derivative, arylomycin C16 (Figure 1), against S. epi-
dermidis are equal to or greater than available clinical antibiotics
(Hellmark et al., 2009), with minimum inhibitory concentrations
(MICs) of 1.0 and 0.25 mg/ml, respectively (Roberts et al., 2007).
Despite their potent activity against S. epidermidis, the known
spectrum of arylomycin activity remained surprisingly narrow.
SPase, which proteolytically removes the N-terminal signal
sequence of proteins translocated across the cytoplasmic
membrane, is conserved in all Eubacteria (Paetzel et al., 2000)
and has been demonstrated to be essential in several key path-
ogens, including E. coli and S. aureus (Cregg et al., 1996; Date,
1983; Zhang et al., 1997). Moreover, although SPase genes
have diverged considerably at the sequence level, they all share
a common fold and catalytic mechanism, and there is significant
sequence conservation in functionally important regions
(denoted as Boxes B–E) (Dalbey et al., 1997), which form the
hydrophobic core, substrate binding cleft, and active site.
Finally, the catalytic domain of SPase is located on the extracel-
lular face of the cytoplasmic membrane; thus, membrane pene-
tration cannot explain the resistance of Gram-positive bacteria
such as S. aureus, although previous reports suggest that the
outer membrane of Gram-negative bacteria prevents the arylo-
mycins and lipoglycopeptides from reaching SPase (Kulanthai-
vel et al., 2004; Roberts et al., 2007). Here, taking advantage of
the sensitivity of S. epidermidis, we use a combination of1, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1223
Figure 1. Chemical Composition of the Arylomycin Class of Natural
Product Antibiotics
Arylomycin A2 has the substituent pattern (R1 = H, R2 = H, R3 = H, R4 = isoC11)
and Arylomycin C16 has the substituent pattern (R1 = H, R2 = H, R3 = H,
R4 = nC15).
Table 1. MICs of arylomycin C16 for S. epidermidis, S. aureus, E.
coli, and P. aeruginosa with Wild-Type or Mutant SPases
Strain SPase SPase Alignment MIC (mg/ml)
S. epidermidis RP62A WT VGKSYSIKGDS 0.25
S. epidermidis PAS9001 S29P VGKPYSIKGDS 8
S. aureus NTCT 8325 WT VAKPYTVKGDS >128
S. aureus PAS8001 P29S VAKSYTVKGDS 2
E. coli MG1655 WT IYEPFQIPSGS >128
E. coli PAS0232 P84S IYESFQIPSGS 4
P. aeruginosa PAO1 WT LFEPFQIPSGS >128
P. aeruginosa PAS2006 P84S LFESFQIPSGS 8
Mutated SPase residues are in boldface.
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Natural Resistance Masks Activity of Arylomycinsgenetic, biochemical, and phylogenetic methods to investigate
the origins of the narrow spectrum of arylomycin activity. We
determine that S. epidermidis evolves arylomycin resistance
via specific SPase mutations and that analogous mutations are
responsible for the natural resistance of many other bacteria.
This, along with the elucidation of a much broader spectrum
than originally believed, which includes Gram-negative bacteria,
suggests that the arylomycins are promising candidates for
development into broad-spectrum antibiotics. Our results also
suggest that naturally occurring resistance may have prevented
the identification of other natural product scaffolds with the
potential for broad-spectrum antibiotic activity.
RESULTS
Point Mutations in SPase Confer Arylomycin Resistance
S. epidermidis is atypically sensitive to the arylomycins (Roberts
et al., 2007). To begin to investigate whether S. epidermidis lacks
specific resistance mechanisms inherent to other bacteria, we
performed selection experiments to isolate mutants that are
able to grow in the presence of 2 mg/ml arylomycin C16 (8 3
MIC). Mutants were obtained at a frequency of 4 per 109 viable
cells and fell into two phenotypic classes. The majority (75%)
have a 32-fold elevated MIC compared with the wild-type strain,
and the remainder have a greater than 256-fold elevated MIC.
Consistent with the low frequency of resistant mutants, we found
that arylomycin resistance is strongly correlated with either of
two point mutations in SpsIB, one of the two SPases found in
S. epidermidis. The 32-fold increase in resistance is associated
with a Ser to Pro mutation at position 29 (10/11 clones
sequenced), while the >256-fold increase in resistance is associ-
ated with a Ser to Pro mutation at position 31 (9/11 clones
sequenced). Neither class of mutants exhibits growth defects
under the standard laboratory conditions employed (see Fig-
ure S1 available online). These data demonstrate that the
whole-cell antibiotic activity of the arylomycins results from their
inhibition of SPase and also that mutations in SPase are the
dominant mechanism whereby S. epidermis evolves resistance.1224 Chemistry & Biology 17, 1223–1231, November 24, 2010 ª2010Next, to investigate whether naturally resistant bacteria harbor
the same mutations that confer resistance in S. epidermidis, we
examined the amino acid sequence of SPases in the closely
related Gram-positive organism S. aureus, as well as in the
more distantly related Gram-negative organisms E. coli and
P. aeruginosa (Table 1). At the position corresponding to residue
31 in S. epidermidis, Pro is not found in any of these SPase
sequences. Moreover, we were unable to construct an E. coli
strain with Pro at this position, suggesting that it is not tolerated
in some organisms. In contrast, at the position corresponding to
residue 29 inS. epidermidis, Pro is found in the single SPase ofS.
aureus, the single SPase of E. coli, and one of the two SPases of
P. aeruginosa (Pro29 in S. aureus, Pro84 in E. coli and
P. aeruginosa).
To determine whether the innate arylomycin resistance
observed in E. coli, P. aeruginosa, and S. aureus results from
the identified Pro residues, we constructed mutant strains of
these bacteria in which Pro is replaced by Ser (the corresponding
residue in wild-type S. epidermidis SpsIB). In each organism,
mutation of Pro to Ser is sufficient to confer a high degree of
sensitivity to arylomycin C16 (Table 1). No growth defects are
apparent in the mutant strains (Figure 2; Figure S1), suggesting
that the increased sensitivity does not result from decreased
fitness under the growth conditions employed, although we
cannot eliminate the possibility that the processing of some
preprotein substrate(s) is affected. Importantly, the sensitivity
of the E. coli and P. aeruginosamutants suggests that the arylo-
mycins penetrate the formidable outer membrane of Gram-
negative bacteria. Consistent with efficient outer-membrane
penetration, we found that permeabilizing these bacteria with
polymyxin B nonapeptide has only a negligible effect on the
MICs (%4-fold decrease).
Next, to determine whether the identified Pro is unique in its
ability to confer arylomycin resistance, we constructed mutant
strains of E. coli in which each of the other 19 amino acids
were introduced into SPase at the same position (residue 84).
Based on the growth rates observed in arylomycin-free media,
most amino acids at this position do not effect fitness under
the conditions employed (Figure 2), although a minor growth
defect (Arg, Lys, Glu, andCys) or a temperature-sensitive pheno-
type (His and Phe) is observed in some strains. In contrast, the
arylomycin C16 MICs are highly dependent on the identity of
the amino acid at residue 84, and Pro is the only amino acidElsevier Ltd All rights reserved
Figure 2. Growth Rates and Arylomycin C16 Sensitivities of E. coli
Strains Harboring the Indicated Amino Acid at SPase Residue 84
Horizontal bars indicate standard deviation of growth rates from three inde-
pendent experiments. MICs varied less than 2-fold between experiments.
His (MIC 4 mg/ml) and Phe (MIC 2 mg/ml) variants have a temperature sensitive
phenotype and are therefore not shown. For Pro29, theMIC exceeds the detec-
tion limit of 256 mg/ml. See also Figure S1.
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Natural Resistance Masks Activity of Arylomycinsthat imparts high-level arylomycin resistance (MIC >256 mg/ml)
(Figure 2). All of the other amino acids confer sensitivity to arylo-
mycin (MICs of %16 mg/ml), with hydrophobic amino acids
conferring somewhat greater sensitivities.Figure 3. Physical and Biochemical Evidence for the Proposed
Mechanism of Arylomycin Resistance
(A) Crystal structure of E. coli SPase in complex with arylomycin A2 (PDB ID
1T7D) (Paetzel et al., 2004). Hydrogen bonds observed in the crystal structure
are shown in green, while the potential hydrogen bond prevented by Pro84 is
shown in red. Equilibrium binding affinities of arylomycin for Pro- and Ser- vari-
ants of E. coli (B) and S. aureus (C) SPases. Data points and bars represent
average values and standard deviations within a single experiment. KD values
shown are the average of three independent experiments. See also Figure S2.Resistance-Conferring Mutations Reduce the Affinity
of Arylomycin for SPase
Based on the previously reported co-crystal structure (Paetzel
et al., 2004), arylomycin A2 binds E. coli SPase in a manner
that mimics that proposed for natural peptide substrates, and
the resistance-conferring Pro residue (Pro84), is positioned
within the substrate binding pocket, but distal to the catalytic
residues (Figure 3A). To test whether the resistance-conferring
mutations directly interfere with arylomycin C16 binding
in vitro, we determined equilibrium binding constants using re-
combinant SPase reconstituted in micelles that mimic
a membrane environment. We first measured the affinity of ar-
ylomycin C16 for the wild-type and P84S variants of a truncated
E. coli SPase that lacks the N-terminal membrane helices, but
still associates with micelles (Kuo et al., 1993) (Figure S2). We
found that arylomycin C16 binds the truncated wild-type protein
with a KD of 979 ± 69 nM, which is similar to the value reported
for arylomycin A2 (Paetzel et al., 2004). In contrast, it binds the
P84S variant with a KD of 39 ± 15 nM. Second, to control for
artifacts associated with deletion of the N-terminal helices,
which might interact with the lipid tail of the inhibitor or help
to colocalize the protein and the inhibitor within the micelles,
we determined the affinities of arylomycin C16 for the wild-
type and P84S variants of detergent-solubilized full-length
E. coli SPase (Figure 3B). While arylomycin C16 binds the full-
length proteins with higher affinities than the corresponding
soluble fragments, the affinity of arylomycin for the full-lengthChemistry & Biology 17, 1223–1231, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1225
Figure 4. Distribution of SPases with Pro29
(or Pro31) Residues Based on Bacterial 16S rRNA
Phylogenies
PhylogeniesofGram-positiveFirmicutesandActinobacte-
ria and Gram-negative Proteobacteria, Bacteroidetes,
and Verrucomicrobia/Chlamydiae based on 16S rRNA
sequences. Species are color codedbyphylogenetic class
(inner color band). Thenumber ofSPases and thepresence
or absence Pro at the relevant positions are indicated by
the length and color(s) of the outer color band. Scale bar
corresponds to a 10% divergence in 16S rRNA sequence.
See also Figures S3 and S4, and Table S1.
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Natural Resistance Masks Activity of ArylomycinsSer variant (KD = 5.7 ± 1.0 nM) is again an order of magnitude
higher than that for the corresponding Pro variant (KD = 60 ±
16 nM). Last, to characterize a representative Gram-positive
SPase, we measured the affinity of arylomycin C16 for the full-
length wild-type and P29S mutant of S. aureus SPase (Fig-
ure 3C). As with the E. coli SPase, arylomycin C16 binds the
Ser variant of S. aureus SPase an order of magnitude more
tightly than the Pro variant, with KD values of 130 ± 53 and
1283 ± 278 nM, respectively. Thus, the Pro residues respon-
sible for resistance in E. coli and S. aureus appear to act by
interfering with arylomycin binding.
Distribution of Resistance-Conferring Residues
in Nature
To better understand the distribution of this resistance determi-
nant in nature, we determined the phylogenetic relationship of
the fully sequenced bacteria from five phyla, as reflected by
their 16S rRNA sequences. We then compared this phylogeny
to the number of SPases in each organism and to the presence
or absence of Pro at the position corresponding to residue 29 in
S. epidermidis (unless otherwise specified, S. epidermidis
numbering is used hereafter). In general, Gram-negative
bacteria from the Chlamydiae/Verrucomicrobia, Proteobacteria,
and Bacteroidetes phyla, have a single SPase, and in each
phylum, Pro29 is present in a subset of organisms (Figure 4).
Accordingly, almost all of the sequenced a-, b-, g-Proteobacte-
ria have SPases with Pro29 (115/123, 64/65, and 178/183 of the
sequenced organisms, respectively), whereas most of the
sequenced d- and 3-Proteobacteria have SPases with Ala291226 Chemistry & Biology 17, 1223–1231, November 24, 2010 ª2010in
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inElsevier Ltd All r(32/35 and 27/29, respectively). Similarly, within
the Bacteroidetes phylum, each of the
sequenced Flavobacteria has one SPase, and
Pro is always present at position 29, whereas
each of the Bacteroidia typically has a SPase
with Asn29 and sometimes a second SPase
with Ser29. Finally, among the few Chlamy-
diae/Verrucomicrobia that have been
sequenced, each of the Chlamydia has one
SPase with Leu29 (7/7), while each of the Verru-
comicrobia has at least one SPase with Pro29
(8/8). The phylogeny of the SPase genes them-
selves largely mirrors that of the 16S rRNA
sequences (Figure S3), indicating that relatively
little horizontal transfer of SPase genes has
occurred and confirming that Pro29 wasstalled independently into the SPases of these lineages. Inter-
stingly, horizontal gene transfer is responsible for the scattered
stances of Proteobacteria that do encode multiple SPases,
cluding the second SPase of P. aeruginosa that has Leu29.
hese additional SPases are not closely related to any of the
equenced SPases examined in this analysis, and they may
ot be functionally equivalent to the other Proteobacterial
Pases.
In contrast to the Gram-negative bacteria, the Gram-positive
irmicutes and Actinobacteria commonly encode multiple
Pases, and comparison of the 16S rRNA and SPase phyloge-
ies indicates that duplication of SPase genes has occurred
ultiple times in these lineages (Figure 4; Figure S3). The distri-
ution of Pro29 is also more irregular, which appears to have
sulted from reduced conservation leading to the frequent intro-
uction and removal of Pro at this position. Moreover, the region
efined by residues 27–31 appears to be poorly conserved
ithin the Gram-positive SPases relative to the same region in
e Gram-negative proteins or to the regions that comprise the
ore and active site of the protein (Table S1). Nonetheless,
ro29 is particularly common among the SPases of the Bacillus,
isteria, and Staphylococcus genera of Firmicutes and the
treptomycetes genus of Actinobacteria. Interestingly, although
Pases with Pro29 appear to have been present and maintained
uring speciation of the Bacilli, Streptomycetes, and Listeria, the
ommon Staphylococcus ancestor appears to have had two
Pases each with Ser29, as is still the case with S. epidermidis.
. aureus appears to have deleted one of these SPases and
troduced Pro29 into the other (Figure S4).ights reserved
Table 2. Associations between Arylomycin C16 Sensitivity and
SPase Genotype(s) among Different Wild-Type Bacteria
Species Residue 29 MIC (mg/ml)
Staphylococcus epidermidis S,S 0.25
Staphylococcus haemolyticus S,S 2
Rhodococcus opacus V 2
Corynebacterium glutamicum M 2
Helicobacter pylori A 4
Yersinia pestis P 4
Chlamydia trachomatis L 6
Francisella tularensis N 416, >64a
Streptococcus pneumoniae N 16
Streptococcus pyogenes A 16
Lactococcus lactis L 16, >128a
Rhodococcus equi V,I 16
Corynebacterium efficiens P >64
Staphylococcus aureus P 12–25, >128a
Brevibacillus brevis P,P,P,P,V >64
Enterococcus faecalis P,P,P,S >64b
Bacillus subtilis P,P,P,D >128
Streptococcus agalactiae F,V >128
Escherichia coli P >128
Pseudomonas aeruginosa P,L >128
Klebsiella pneumoniae P >128
Lactobacillus sakei P,N >128
Lactobacillus gasseri N,N >128
Lactobacillus acidophilus N >128
Lactobacillus plantarum M,M,V >128
Clostridium difficile P,P,P >16
Clostridium bolteae N,N,Q >16
Clostridium perfringens K,K,K,I >16
Bacteroides fragilis S,N >16
Prevotella copris N >16
aMultiple values indicate heterogeneity within different strains of
a species, as discussed in the text.
bDetermined previously (Roberts et al., 2007).
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Natural Resistance Masks Activity of ArylomycinsThe Arylomycins Have a Broad Spectrum of Antibiotic
Activity
To further explore the spectrum of arylomycins and to test the
contribution of the Pro29 to arylomycin resistance in a wider
range of bacteria, we determined the arylomycin susceptibilities
of representative organisms from the above phylogenetic anal-
ysis (Table 2). Bacteria from all five phyla were sampled, and
when possible important human pathogens were included.
Consistent with our expectations, arylomycin C16 is active
against the 3-Proteobacteria H. pylori (whose SPase has Ala29)
with an MIC of 4 mg/ml. Similarly, the intracellular Gram-negative
pathogen C. trachomatis (Leu29) is eradicated from human HeLa
229 cells with an MIC of 6 mg/ml. Notably, no adverse effects on
the human cells were observed up to 20 mg/ml of arylomycin, the
highest concentrations examined. With Francisella tularensis
(Asn29), a potential biological warfare agent and a member of
the only genera of g-Proteobacteria that does not have Pro29,Chemistry & Biology 17, 1223–123we examined 19 clinical isolates and found that 8 are inhibited
with MICs of 4–16 mg/ml, 1 with an MIC of 32 mg/ml, and the
remainder with MICs in excess of 64 mg/ml. Klebsiella pneumo-
niae encodes a single SPase that has Pro29 and is resistant to
the arylomycins. Interestingly, although its single SPase has
Pro29, Yersinia pestis, the causative agent of plague, is sensitive
to arylomycin C16.
The Gram-positive Firmicutes Streptococcus pneumoniae,
Streptococcus pyogenes, and Staphylococcus haemolyticus,
are all human pathogens that lack SPases with Pro29. As
predicted, we find that each is sensitive to arylomycin C16.
Also as predicted, we find that B. subtilis and E. faecalis, Firmi-
cutes with multiple SPases with Pro29, are resistant. Interest-
ingly, we that find Brevibacillus brevis, which was previously
reported to be moderately sensitive to the arylomycins
(Schimana et al., 2002), grows in the presence of more than
64 mg/ml, as predicted from its four encoded SPases with
Pro29. Within the Gram-positive Actinobacteria, Rhodococcus
equi, like Rhodococcus opacus (Schimana et al., 2002) is sensi-
tive to the arylomycins, and both lack Pro29. While the actinobac-
teria Corynebacterium glutamicum has a single SPase with
Met29 and an arylomycin C16 MIC of 2 mg/ml, the related actino-
bacteria Corynebacterium efficiens has a single SPase with
Pro29 and an MIC of greater than 64 mg/ml. However, we also
found Gram-positive bacteria for which the model was not as
predictive. For example, while Lactococcus lactis spp. cremonis
has a single SPase with Leu29 and is sensitive to arylomycin C16,
the highly related Lactococcus lactis spp. lactii also has a single
SPase with Leu29 and is resistant. Additionally, we found that
a variety of other Lactobacillales, and all investigated Clostridia
and Bacteriodetes, are resistant to the arylomycins despite the
fact that many lack SPases with Pro29 (MIC >64 mg/ml for the
Lactobacillales and >16 mg/ml for the Clostridia and Bacterio-
detes). Finally, a broader survey of S. aureus strains revealed
two, COL, a tetracycline and penicillin-resistant strain
(MIC = 12 mg/ml), and Rosenbach 328, an MRSA strain (Pantosti
and Venditti, 2009) (MIC = 25 mg/ml), are moderately sensitive
despite having SPases with Pro29.
DISCUSSION
The four decades following the discovery of penicillin, saw the
development of almost all of the major classes of broad-spec-
trum antibiotics in use today. While these antibiotics revolution-
ized the treatment of infectious disease, the more recent
decades have witnessed the systematic and relentless evolution
of resistant bacteria, and discovery efforts have failed to provide
a novel class for clinical use. While many narrow-spectrum anti-
biotics have been identified, these compounds are typically
assumed to inhibit targets that are poorly conserved, not univer-
sally essential, or not accessible, and therefore these
compounds are not typically considered for commercial devel-
opment (Lambert, 2002; Payne et al., 2007). One such class of
novel natural products is the arylomycins, which despite inhibit-
ing an essential target with a conserved active site, appeared to
have a prohibitively narrow spectrum of whole-cell activity.
Although it was proposed that they do not penetrate the outer
membrane of Gram-negative bacteria (Kulanthaivel et al.,
2004; Roberts et al., 2007), their lack of activity against most1, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1227
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Natural Resistance Masks Activity of ArylomycinsGram-positive bacteria has remained more enigmatic. We find
that activity against the important human pathogens S. aureus,
E. coli, and P. aeruginosa is not limited by target conservation,
essentiality, or accessibility, but rather by the presence of
a specific SPase residue, Pro29, which we initially identified by
characterizing how the naturally sensitive organism S. epidermi-
dis evolves resistance. For both the E. coli andS. aureus SPases,
we also demonstrated that the presence of Pro at this position
confers resistance by reducing the affinity with which SPase is
bound by the arylomycins.
A physical basis for the observed resistance mechanism is
suggested by the structure of arylomycin A2 bound to wild-
type E. coli SPase solved by Paetzel et al. (2004) (Figure 3A).
Themacrocyclic core packs into the deep SPase active-site cleft
and forms critical contacts with the catalytic residues and with
the residues that comprise the P3 substrate binding pocket.
Moreover, each hydrogen-bond donor/acceptor of the peptide
backbone portion of the macrocycle engages the protein. In
contrast, the three residues N-terminal to the macrocycle
interact only with a shallow groove and form only two hydrogen
bonds, each between backbone residues of the inhibitor and
protein. Residue 84 (corresponding to residue 29 in S. epidermi-
dis SpsIB) is located within this region, and reduced inhibitor-
protein interactions are consistent with our finding that many
amino acids at this position result in similar arylomycin sensitiv-
ities. However, the backbone amide of residue 84 appears to be
positioned to form a stabilizing hydrogen bond with the carbonyl
oxygen of the arylomycin fatty acid tail, an interaction that is
uniquely ablated by mutation to Pro, which lacks an amide
proton. Similarly, the hydrogen bond between Gln86 (corre-
sponding to residue 31, the alternative resistance conferring
residue in S. epidermidis) and arylomycin Gly4 would be ablated
by mutation to Pro, likely explaining why it also confers
resistance in S. epidermidis, while the proximity of this mutation
to the catalytic residues may explain why it is not tolerated in
some organisms. Moreover, hydrophobic amino acids at
position 84 might promote desolvation of the backbone amide
in the unbound state, which would favor arylomycin binding
and account for the greater sensitivity conferred by these amino
acids relative to their more polar counterparts.
The degree of conservation of the region surrounding residue
29 varies from low within Gram-positive bacteria, to relatively
high within the Proteobacteria, and contrasts with the extreme
conservation of the residues that more immediately surround
the catalytic site and form the critical P1 and P3 substrate
binding pockets. Interestingly, the sequence of the preprotein
substrates cleaved by SPases are strongly conserved only at
positions1 and3 relative to the cleavage site, where Ala resi-
dues are almost exclusively encoded (Choo and Ranganathan,
2008; Paetzel et al., 2002). Thus, as with the arylomycins, the
natural substrates do not appear to make side-chain-specific
interactions with SPase in the region surrounding residue 29,
which likely contributes to the observed sequence divergence
in this region of enzyme. The presence of multiple paralogous
SPases in many Gram-positive bacteria may further reduce the
constraints on SPase divergence and contribute to the sporadic
distribution of Pro29 in the SPases of these bacteria. Interest-
ingly, the relatively high sequence conservation within the region
surrounding residue 29 of SPase from Gram-negative Proteo-1228 Chemistry & Biology 17, 1223–1231, November 24, 2010 ª2010bacteria suggests that this residue plays an important role in
SPase function, despite the results of our model studies with
E. coli where most residues are well tolerated at this position.
Thus, whatever the role of Pro29, it is not manifest under labora-
tory conditions and must instead be unique to the demands of
protein secretion in the organism’s natural environments (Papp
et al., 2004).
Using Pro29 as a sequence signature of arylomycin resistance,
we identified many diverse bacteria, including important human
pathogens, that lack this residue and then confirmed that many
of these bacteria have MICs less than or equal to 16 mg/ml
(Table 2), potencies reasonable from the perspective of drug
development. While the absence of Pro29 is often predictive of
arylomycin sensitivity, the absolute sensitivity varies between
different species. For example, while R. opacus and R. equi
are closely related and lack SPases with Pro29, their sensitivities
to arylomycin C16 differ by 8-fold. Similarly, wild-type S. epider-
midis, which its natural Ser29 SPase, is 8-foldmore sensitive than
the Ser29 mutant of S. aureus. Furthermore, some organisms are
highly resistant to the arylomycins in the absence of SPases with
Pro29, including many of the Lactobacillales, Clostridia, and
Bacteriodetes. Conversely, Y. pestis and several strains of
S. aureus, including a clinical isolate of MRSA, which were pre-
dicted to be resistant, are, in fact, sensitive. Taken together,
these data suggest that other factors also contribute to the abso-
lute level of arylomycin sensitivity, possibly including other
variations in SPase sequence, differences in SPase expression
levels, differences in the levels of protein secretion required for
growth, or the presence of yet to be identified modifying
enzymes or efflux pumps. Alternatively, certain strains could
be hypersusceptible to the inhibition of secretion as a result of
the accumulation of specific toxic proteins.
The arylomycins are active against a wide range of bacteria,
including both Gram-negative and Gram-positive organisms,
and are therefore not narrow spectrum. The term ‘‘narrow spec-
trum’’ is typically reserved for antibiotics that inhibit targets that
are only accessible, essential, and sufficiently conserved within
specific bacterial taxa. These limitations preclude the expansion
of the scaffold’s spectrum to entire groups of other bacteria. For
example, polymyxin B selectively destabilizes Gram-negative
membranes (Evans et al., 1999), daptomycin selectively destabi-
lizes Gram-positive membranes (Tally and DeBruin, 2000), and
fosmidomycin inhibits a component of a metabolic pathway
that is not present in many bacteria (Jomaa et al., 1999). More-
over, large or excessively hydrophobic antibiotics, such as
vancomycin, are unable to penetrate the outer membranes of
Gram-negative bacteria (Nikaido, 2003). In contrast, the arylo-
mycins penetrate permeability barriers including the lipid rich
cell wall of Corynebacterium (Lambert, 2002) and the outer
membranes of Gram-negative bacteria (Nikaido, 2003), interact
primarily with a highly conserved region of SPase, and conse-
quently have activity against a remarkably diverse range of
bacteria. This is reflected by the lack of correlation between ar-
ylomycin sensitivity and overall phylogenetic relatedness. The
reduced spectrum of the arylomycins results instead from their
interactions with a less conserved region of SPase where
a specific resistance conferring mutation naturally occurs in
some SPases. From an evolutionary perspective, this might
suggest that the arylomycins were selected for activity againstElsevier Ltd All rights reserved
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Natural Resistance Masks Activity of Arylomycinsa specific competitor that lacked a resistance-conferring
residue. Alternatively, arylomycin biosynthesis may have
emerged early in bacterial evolution before this region of SPase
diverged, and in this case, it is possible that selection by arylo-
mycin contributed in some instances to the fixation of Pro29.
Investigating the antiquity and prevalence of arylomycin biosyn-
thesis should shed light on this fascinating possibility. From
a medicinal chemistry perspective, the results suggest that an
arylomycin derivative modified to bind with increased affinity to
the conserved catalytic region of SPase, and to rely less on inter-
actions with the more variable regions, would be active against
most bacteria.
Importantly, our results also emphasize that specific resis-
tance mechanisms in several bacteria commonly used to screen
for novel antibiotics can prevent the identification of scaffolds
with the potential for development into broad-spectrum thera-
peutics. The pharmaceutical industry discovered the arylomycin
class of antibiotics only after screening a library of purified
natural products for activity in an in vitro SPase assay, and
they would not likely have been identified using a whole-cell
assay. Combined with the recently recognized high frequency
of natural resistance to known antibiotics (D’Costa et al., 2006,
2007; Riesenfeld et al., 2004; Waters and Davies, 1997), our
results raise the possibility that the broad-spectrum potential
of other hits identified from in vitro assay may have been obfus-
cated and that novel classes of antibiotics may have been
missed entirely in whole-cell screens. Thus, additional ‘‘latent
antibiotics’’ might be identified by more careful examination of
known apparently narrow-spectrum antibiotics, especially
where resistance patterns are uneven across phylogenetically
related species, or by expanding the set of bacteria tested during
drug discovery efforts to include a broader range of phylogenet-
ically diverse bacteria. Given the well-established precedent for
optimizing suitable antibiotic scaffolds to overcome specific
mechanisms of resistance, as evidenced by the successful
development of many ‘‘next-generation’’ variants of antibiotics
that possess broader spectra of activity (Essack, 2001; Gootz,
1990; Hammerschlag and Sharma, 2008; Schneider et al.,
2003), the discovery of additional latent antibiotics could provide
invaluable scaffolds for optimization into broad-spectrum
antibiotics.
SIGNIFICANCE
Natural products have proved to be the most fruitful source
of antibiotics, but discovering novel natural products with
broad-spectrum activity has proved difficult, and it has
been almost fifty years since a novel class of broad-spec-
trum antibiotics was introduced into the clinic. The arylomy-
cin class of natural products originally elicited significant
interest due to their in vitro inhibition of type I signal pepti-
dase (SPase), a promising antibiotic target. However, the
arylomycins were soon found to be inactive against many
important pathogens, and like many antibiotics with
a narrow spectrum of activity, they were then dismissed as
potential therapeutics. Herein, we show that when chal-
lenged with arylomycin, the naturally sensitive organism
Staphylococcus epidermidis evolves resistance via muta-
tions in SPase. Unexpectedly, we find that the analogousChemistry & Biology 17, 1223–123mutations are naturally present in SPases of many bacteria,
including those of the important human pathogens Staphy-
lococcus aureus, Escherichia coli, and Pseudomonas aeru-
ginosa, and we confirm that they are responsible for the
natural resistance of these pathogens. We identify diverse
bacteria lacking SPases with these mutations and demon-
strate that most are sensitive to the arylomycins, and in
doing so we greatly expand the known activity spectrum of
the arylomycins to include organisms from four distinct
phyla. Thus, the arylomycins are bona fide broad-spectrum
antibiotics. Although the presence of resistance conferring
mutation in key pathogens currently limits the therapeutic
utility of these molecules, historical precedent suggests
that natural product scaffolds can be modified to overcome
specific resistance mechanisms. Thus, the arylomycins are
valuable leads for antibiotic development. Importantly, our
results also demonstrate that resistance mechanisms in
the bacteria commonly used to screen for antibiotics can
prevent the identification of promising scaffolds and conse-
quently that valuable leads for antibiotic development may
still lie undetected among available natural products.
EXPERIMENTAL PROCEDURES
Strains and Culture Conditions
Standard methods were used to culture bacteria for all experiments and to
construct mutant strains; details and a description of the strains used in this
study are provided in the Supplemental Experimental Procedures.
Selection of Arylomycin-Resistant S. epidermidis and Sequencing of
Signal Peptidase Genes
S. epidermidis (13 109 cfu) were plated on tryptic soy agar (TSA) containing
2 mg/ml arylomycin C16. Resistant colonies visible at 24 hr were restreaked
onto TSA containing 2 mg/ml arylomycin C16 to confirm the resistant pheno-
type. Isolation of genomic DNA and sequencing of SPases genes is described
in the Supplemental Experimental Procedures.
Minimum Inhibitory Concentration Experiments
With the exception ofC. trachomatis andH. pylori, minimum inhibitory concen-
trations of arylomycin C16 were determined by a modified CLSI microbroth
dilution method in 100 ml of media containing 2-fold dilutions of arylomycin
C16. Media and growth conditions used for MIC experiments, as well as
a detailed description of the determination of the arylomycin MICs for
C. trachomatis and H. pylori are described in the Supplemental Experimental
Procedures.
In Vitro KD Measurements
Construction of expression vectors and the subsequent production of the
various SPase variants used in this study are described in the Supplemental
Experimental Procedures. Steady-state binding of arylomycin C16 was deter-
mined by measuring the previously described increase in arylomycin fluores-
cence (lex = 320 nm, lem = 410 nm) upon binding E. coli D2-75 SPase (Paetzel
et al., 2004). The binding buffer for full length and truncated E. coli proteins was
as follows: 100 mMNaCl, 20 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1% n-octyl-b-
glucopyranoside (Anatrace). This buffer was supplemented with 10% glycerol
for experiments with S. aureus SPase protein.
SPase Sequence Analysis
The amino acid sequences of the SPases from E. coli, S. aureus,B. fragilis, and
C. efficiens were concatenated and used as the query sequence in a BLAST
against all of the fully sequenced genomes of Bacteriodetes, Actinobacteria,
Firmicutes, Proteobacteria, and Chlamydiae/Verrucomicrobia available in
the NCBI Microbial Genome Database. The amino acid sequence of BLAST
hits with an E-value less than 0.1 were aligned using MUSCLE (Edgar, 2004),1, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1229
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Poorly aligned regions were removed using the ‘‘BlockMapping and Gathering
using Entropy’’ program found at http://mobyle.pasteur.fr/cgi-bin/portal.py,
with Gap Rate Cutoff 0.3 and the Entropy Cutoff of 0.7. Phylogenetic analysis
was conducted using PhyML 3.0 with 20 rate categories and SPR branch
improvement (Guindon and Gascuel, 2003). SPases from Gram-positive and
Gram-negative organisms were kept separate during alignment and phyloge-
netic analysis to improve the quality of these analyses. Also several SPases
from the Gram-negative Proteobacteria were removed prior to analysis of
SPase phylogeny, since they did not show an obvious relation to any of the
other Gram-negative or Gram-positive SPases examined. Phylogenetic trees
were displayed using the Interactive Tree of Life (Letunic and Bork, 2007).
16S rRNA Sequence Analysis
Aligned 16S rRNA sequences were analyzed were obtained from the Ribo-
somal Database Project (Cole et al., 2009). The ‘‘BlockMapping and Gathering
using Entropy’’ program was used with a Gap Rate Cutoff of 0.7 and an
Entropy Cutoff of 0.7 to remove poorly aligned regions. Phylogenetic analysis
was performed using PhyML 3.0, with the HKY85 substitution model with 20
rate categories and SPR branch improvement, and the resulting tree was dis-
played using the Interactive Tree of Life (Letunic and Bork, 2007).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at
doi:10.1016/j.chembiol.2010.09.009.
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